Dual effect of nitric oxide donor on adjuvant arthritis.
The effect of medical use of NO donors on the pathogenesis of arthritis is still yet unclear. We investigated the effects of the NO donor, sodium nitroprusside (SNP), on the pathogenesis of adjuvant-induced arthritis in rats. Rats were given SNP intraperitoneally either from day 5 to day 14 (as a prophylactic protocol) or from day 16 to day 25 (as a therapeutic protocol) after inoculation of adjuvant. SNP administration, whether prophylactic or therapeutic, in doses of 0.1 and 1 mg/kg/d significantly aggravated pathogenesis of adjuvant arthritis in rats. SNP-treated rats showed significant (P<0.05) increase in arthritis index, hind paw volume, ankle joint diameter and hyperalgesia compared with control adjuvant arthritic rats. However, in adjuvant rats given the smallest dose of SNP (0.01 mg/kg/d), arthritis index, volume of hind paws, ankle joint diameter, body weight loss, and hyperalgesia were significantly lower than that of control adjuvant rats. After 30 d of the induction of adjuvant arthritis, TNF alpha levels exhibited insignificant changes either in control adjuvant rats or in rats given SNP compared with control non adjuvant rats. IL-10 levels in adjuvant control rats and adjuvant rats given 1 mg or 0.1 mg/kg/d from day 15 to day 25 were significantly lower than that of control non adjuvant rats. Histopathology examination of ankle joint showed that large doses of SNP (1 mg or 0.1 mg/kg/d) increased the mononuclear cells infiltration and erosion of cartilage induced by adjuvant while the infiltration of the inflammatory cells in the synovium of adjuvant rats treated with 0.01 mg/kg/d was minimal and the pannus was inhibited with alleviation of erosion of articular cartilage. Prophylactic small dose of SNP improved the histological status more than the therapeutic small dose. The present work reveals that SNP administration, either prophylactic or therapeutic, was deleterious in higher doses. However, the smallest dose used 0.01 mg/kg/d attenuates joint inflammation, hyperalgesia and body weight loss in adjuvant arthritic rats. These results suggest that small dose of NO donor may exert partial protective effects while the safety of the clinical use of NO donors, in higher doses, in patients with rheumatoid arthritis is questioned.
Gomaa
Adel A
AA
Department of Pharmacology, Faculty of Medicine, Assiut University, Assiut, Egypt. a.gomma@aun.edu.eg
Elshenawy
Mohsen M
MM
Afifi
Noha A
NA
Mohammed
Eman A
EA
Thabit
Romany H
RH
D000818:Animals; D000843:Ankle Joint / Q000276:immunology / Q000473:pathology; D001169:Arthritis, Experimental / Q000188:drug therapy* / Q000276:immunology; D004195:Disease Models, Animal; D005260:Female; D005620:Freund's Adjuvant / Q000494:pharmacology; D016753:Interleukin-10 / Q000097:blood; D020030:Nitric Oxide Donors / Q000008:administration & dosage* / Q000009:adverse effects; D009599:Nitroprusside / Q000008:administration & dosage* / Q000009:adverse effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D020030:Nitric Oxide Donors; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D009599:Nitroprusside; D005620:Freund's Adjuvant